摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-(1,1-Difluoroethyl)-5-(4-{4-methyl-5-[2-(trifluoromethyl)phenyl]-4H-1,2,4-triazol-3-yl}bicyclo[2.2.2]oct-1-yl)-1,3,4-oxadiazole | 935273-81-7

中文名称
——
中文别名
——
英文名称
2-(1,1-Difluoroethyl)-5-(4-{4-methyl-5-[2-(trifluoromethyl)phenyl]-4H-1,2,4-triazol-3-yl}bicyclo[2.2.2]oct-1-yl)-1,3,4-oxadiazole
英文别名
2-(1,1-difluoroethyl)-5-[4-[4-methyl-5-[2-(trifluoromethyl)phenyl]-1,2,4-triazol-3-yl]-1-bicyclo[2.2.2]octanyl]-1,3,4-oxadiazole
2-(1,1-Difluoroethyl)-5-(4-{4-methyl-5-[2-(trifluoromethyl)phenyl]-4H-1,2,4-triazol-3-yl}bicyclo[2.2.2]oct-1-yl)-1,3,4-oxadiazole化学式
CAS
935273-81-7
化学式
C22H22F5N5O
mdl
——
分子量
467.442
InChiKey
NJIFUSHVKTYKOQ-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    4.2
  • 重原子数:
    33
  • 可旋转键数:
    4
  • 环数:
    6.0
  • sp3杂化的碳原子比例:
    0.55
  • 拓扑面积:
    69.6
  • 氢给体数:
    0
  • 氢受体数:
    10

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为产物:
    描述:
    4-{4-methyl-5-[2-(trifluoromethyl)phenyl]-4H-1,2,4-triazol-3-yl}bicyclo[2.2.2]octane-1-carbohydrazide2,2-二氟丙酸氮气碳酸氢钠 、 Brine 、 crude product 作用下, 以 二氯甲烷 为溶剂, 反应 48.0h, 以to give 4-B as a white solid的产率得到2-(1,1-Difluoroethyl)-5-(4-{4-methyl-5-[2-(trifluoromethyl)phenyl]-4H-1,2,4-triazol-3-yl}bicyclo[2.2.2]oct-1-yl)-1,3,4-oxadiazole
    参考文献:
    名称:
    Triazole derivatives which are SMO antagonists
    摘要:
    本发明提供了一种治疗或预防可通过Smo拮抗改善的病症的方法,该方法包括向需要治疗的患者施用式I的化合物或包含式I的化合物的组合物的有效量,或其药学上可接受的盐或溶剂;其中:X、Y和Z中的2个代表氮原子,另一个代表氧原子;R1和R2与它们附着的原子结合在一起,代表一个环丁基环,可选地取代1-2个氟原子,且R3代表氢或氟原子;或R1代表甲基,R2代表甲基或氟原子,且R3代表氟原子。
    公开号:
    US20080262051A1
点击查看最新优质反应信息

文献信息

  • HETEROCYCLIC DERIVATIVES AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE
    申请人:Isabel Elise
    公开号:US20110301143A1
    公开(公告)日:2011-12-08
    Heterocyclic compounds of structural formula (I), or a pharmaceutically acceptable salt thereof, wherein W is a R 1 — substituted heteroaryl, R 1 is an heteroaryl ring substituted with an ester or carboxylic acid containing radical, X-T is N—CR 5 R 6 , C═CR 5 or CR 13 —CR 5 R 6 , Y is a bond or —C(O)—, a and b represent an integer selected from 1 to 4, and Ar is an optionally substituted phenyl or naphtyl, are inhibitors of stearoyl-coenzyme A delta-9 desaturase (SCD) The heterocyclic compounds are useful for the prevention and treatment of conditions related to abnormal lipid synthesis and metabolism, including cardiovascular disease, atherosclerosis, obesity, diabetes, neurological disease, Metabolic Syndrome, insulin resistance, cancer, liver steatosis, and non-alcoholic steatohepatitis.
    结构式(I)的杂环化合物,或其药学上可接受的盐,其中W是R1-取代的杂芳基,R1是取代有酯基或羧基的杂芳基环,X-T是N—CR5R6,C═CR5或CR13—CR5R6,Y是键或—C(O)—,a和b代表选自1到4的整数,Ar是可选择取代的苯基或萘基,是硬脂酰辅酶A 9-脱饱和酶(SCD)的抑制剂。这些杂环化合物对于预防和治疗与异常脂质合成和代谢有关的疾病非常有用,包括心血管疾病、动脉粥样硬化、肥胖症、糖尿病、神经系统疾病、代谢综合征、胰岛素抵抗、癌症、肝脂肪变性和非酒精性脂肪肝。
  • AMINOTETRAHYDROPYRANS AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES
    申请人:Biftu Tesfaye
    公开号:US20100120863A1
    公开(公告)日:2010-05-13
    The present invention is directed to novel substituted aminotetrahydropyrans of structural formula I which are inhibitors of the dipeptidyl peptidase-IV enzyme and which are useful in the treatment or prevention of diseases in which the dipeptidyl peptidase-IV enzyme is involved, such as diabetes and particularly Type 2 diabetes. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which the dipeptidyl peptidase-IV enzyme is involved.
    本发明涉及结构式I的新型取代氨基四氢吡喃衍生物,它们是二肽基肽酶-IV酶的抑制剂,可用于治疗或预防二肽基肽酶-IV酶参与的疾病,如糖尿病,特别是2型糖尿病。该发明还涉及包含这些化合物的药物组合物,以及这些化合物和组合物在预防或治疗二肽基肽酶-IV酶参与的疾病中的用途。
  • [EN] AZETIDINE DERIVATIVES AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE<br/>[FR] DÉRIVÉS D'AZÉTIDINE COMME INHIBITEURS DE LA STÉAROYL-COENZYME A DELTA-9 DÉSATURASE
    申请人:MERCK FROSST CANADA LTD
    公开号:WO2010043052A1
    公开(公告)日:2010-04-22
    Azetidine derivatives of structural formula I are inhibitors of stearoyl-coenzyme A delta-9 desaturase (SCD). The compounds of the present invention are useful for the prevention and treatment of conditions related to abnormal lipid synthesis and metabolism, including cardiovascular disease; atherosclerosis; obesity; diabetes; neurological disease; Metabolic Syndrome; insulin resistance; cancer; liver steatosis; and non-alcoholic steatohepatitis.
    结构式I的氮杂环丙烷衍生物是硬脂酰辅酶A 9-脱饱和酶(SCD)的抑制剂。本发明的化合物对于预防和治疗与异常脂质合成和代谢相关的疾病非常有用,包括心血管疾病;动脉粥样硬化;肥胖;糖尿病;神经系统疾病;代谢综合征;胰岛素抵抗;癌症;肝脂肪变性;以及非酒精性脂肪肝。
  • [EN] HETEROCYCLIC COMPOUNDS AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE<br/>[FR] COMPOSÉS HÉTÉROCYCLIQUES INHIBITEURS DE LA STÉAROYL-COENZYME A DELTA-9 DÉSATURASE
    申请人:MERCK FROSST CANADA LTD
    公开号:WO2010108268A1
    公开(公告)日:2010-09-30
    Heterocyclic compounds of structural formula I are inhibitors of stearoyl-coenzyme A delta-9 desaturase (SCD). The compounds of the present invention are useful for the prevention and treatment of conditions related to abnormal lipid synthesis and metabolism, including cardiovascular disease; atherosclerosis; obesity; diabetes; neurological disease; Metabolic Syndrome; insulin resistance; cancer, liver steatosis; and non-alcoholic steatohepatitis.
    结构式I的杂环化合物是硬脂酰辅酶A Δ-9去饱和酶(SCD)的抑制剂。本发明的化合物对于预防和治疗与异常脂质合成和代谢相关的疾病非常有用,包括心血管疾病;动脉粥样硬化;肥胖;糖尿病;神经系统疾病;代谢综合征;胰岛素抵抗;癌症;肝脂肪变性;以及非酒精性脂肪性肝炎。
  • Triazole derivatives which are SMO antagonists
    申请人:Balkovec James M.
    公开号:US20080262051A1
    公开(公告)日:2008-10-23
    The present invention provides a method for the treatment or prevention of conditions which can be ameliorated by Smo antagonism, which method comprises administration to a patient in need thereof of an effective amount of a compound of formula I or a composition comprising a compound of formula I: or a pharmaceutically acceptable salt or solvate thereof; wherein: 2 of X, Y and Z represent nitrogen atoms, and the other represents an oxygen atom; R 1 and R 2 are taken together with the atom to which they are attached and represent a cyclobutyl ring, optionally substituted with 1-2 fluorine atoms, and R 3 represents hydrogen or a fluorine atom; or R 1 represents methyl, R 2 represents methyl or a fluorine atom and R 3 represents a fluorine atom.
    本发明提供了一种用于治疗或预防可以通过Smo拮抗改善的疾病的方法,该方法包括向需要的患者施用化合物I的有效剂量或包含化合物I的组合物:或其药学上可接受的盐或溶剂;其中:X、Y和Z中的2个表示氮原子,另一个表示氧原子;R1和R2与它们连接的原子一起表示一个环丁基环,可选地取代1-2个氟原子,R3表示氢或氟原子;或R1表示甲基,R2表示甲基或氟原子,R3表示氟原子。
查看更多

同类化合物

伊莫拉明 (5aS,6R,9S,9aR)-5a,6,7,8,9,9a-六氢-6,11,11-三甲基-2-(2,3,4,5,6-五氟苯基)-6,9-甲基-4H-[1,2,4]三唑[3,4-c][1,4]苯并恶嗪四氟硼酸酯 (5-氨基-1,3,4-噻二唑-2-基)甲醇 齐墩果-2,12-二烯[2,3-d]异恶唑-28-酸 黄曲霉毒素H1 高效液相卡套柱 非昔硝唑 非布索坦杂质Z19 非布索坦杂质T 非布索坦杂质K 非布索坦杂质E 非布索坦杂质67 非布索坦杂质65 非布索坦杂质64 非布索坦杂质61 非布索坦代谢物67M-4 非布索坦代谢物67M-2 非布索坦代谢物 67M-1 非布索坦-D9 非布索坦 非唑拉明 雷西纳德杂质H 雷西纳德 阿西司特 阿莫奈韦 阿米苯唑 阿米特罗13C2,15N2 阿瑞匹坦杂质 阿格列扎 阿扎司特 阿尔吡登 阿塔鲁伦中间体 阿培利司N-1 阿哌沙班杂质26 阿哌沙班杂质15 阿可替尼 阿作莫兰 阿佐塞米 镁(2+)(Z)-4'-羟基-3'-甲氧基肉桂酸酯 锌1,2-二甲基咪唑二氯化物 铵2-(4-氯苯基)苯并恶唑-5-丙酸盐 铬酸钠[-氯-3-[(5-二氢-3-甲基-5-氧代-1-苯基-1H-吡唑-4-基)偶氮]-2-羟基苯磺酸基][4-[(3,5-二氯-2-羟基苯 铁(2+)乙二酸酯-3-甲氧基苯胺(1:1:2) 钠5-苯基-4,5-二氢吡唑-1-羧酸酯 钠3-[2-(2-壬基-4,5-二氢-1H-咪唑-1-基)乙氧基]丙酸酯 钠3-(2H-苯并三唑-2-基)-5-仲-丁基-4-羟基苯磺酸酯 钠(2R,4aR,6R,7R,7aS)-6-(2-溴-9-氧代-6-苯基-4,9-二氢-3H-咪唑并[1,2-a]嘌呤-3-基)-7-羟基四氢-4H-呋喃并[3,2-D][1,3,2]二氧杂环己膦烷e-2-硫醇2-氧化物 野麦枯 野燕枯 醋甲唑胺